Assay drift during shared facility campaign: FDA/EMA investigation expectations



Published on 30/12/2025

Understanding Assay Drift During Shared Facility Campaigns: Investigation Framework for Regulatory Compliance

Assay drift can pose significant challenges during shared facility campaigns, especially in an environment where cross-contamination might occur. Given the regulatory scrutiny from agencies such as the FDA, EMA, and MHRA, it is crucial to implement a robust investigation framework that ensures compliance and maintains product quality. This article outlines a systematic approach to investigate assay drift, providing practical guidance for pharmaceutical manufacturing and quality professionals.

We will explore the symptoms of assay drift, identify probable causes, suggest immediate containment actions, and detail an investigation workflow. Additionally, we’ll delve into root cause analysis tools, CAPA strategies, control measures, and inspection readiness, equipping you to effectively manage such deviations in compliance with GMP standards.

Symptoms/Signals on the Floor or in the Lab

Identifying symptoms of assay drift is the first step in effective investigation. Symptoms may manifest as deviations in test results, unexpected trends

in data, or quality complaints from customers. Common signals include:

  • Out-of-Specification (OOS) Results: A product’s assay results fall outside the established acceptance criteria, leading to potential batch rejection.
  • Statistical Trends: A consistent deviation from expected results over time may indicate assay instability.
  • Customer Complaints: Reports from end users regarding unexpected efficacy or safety concerns related to product performance.
  • Issues During Stability Testing: Unexpected deterioration of assay performance during stability assessments.

Recognizing these symptoms early allows for swift action, minimizing the impact on operations and compliance with regulatory requirements.

Likely Causes

Understanding the root causes of assay drift can enhance the investigation process. Potential causes can be categorized into several areas:

  • Materials:
    • Quality of raw materials
    • Stability of standards used for assays
  • Method:
    • Inconsistent assay methodologies
    • Improper calibration of instrumentation
  • Machine:
    • Equipment malfunction or performance degradation
    • Improper maintenance or calibration of equipment
  • Man:
    • Operator training and competence
    • Human errors in sampling or data recording
  • Measurement:
    • Inaccurate measurement techniques
    • Lack of controls to verify assay readouts
  • Environment:
    • Fluctuations in laboratory conditions (temperature, humidity)
    • Cross-contamination between products in shared facilities
Pharma Tip:  Potency OOS during shared facility campaign: FDA/EMA investigation expectations

This categorization aids in systematically identifying the likely sources of assay drift.

Immediate Containment Actions (First 60 Minutes)

The first hour of identifying assay drift is critical for containment and mitigation. Essential actions include:

  1. Pause Production: Immediately halt any ongoing manufacturing processes related to the suspect product.
  2. Review Batch Records: Retrieve and review production and testing batch records to ensure all aspects are within bounds.
  3. Isolate Affected Batches: Quarantine all batches affected or potentially affected by the assay drift.
  4. Notify Regulatory Affairs: Inform the regulatory affairs department of the deviation, ensuring compliance with reporting requirements.
  5. Conduct Preliminary Investigations: Gather relevant data related to the incident, such as environmental monitoring data and equipment logs.

These immediate containment actions establish a foundation for a thorough investigation and demonstrate proactive responses to regulatory bodies.

Investigation Workflow

Implementing a structured investigation workflow is essential to uncover root causes of assay drift. The steps in this workflow involve:

  1. Data Collection: Gather all pertinent data, including batch records, stability data, equipment maintenance logs, and personnel training records.
  2. Interviews and Audits: Conduct interviews with personnel involved in the assay process and audit related areas to gather qualitative information.
  3. Trend Analysis: Analyze historical data trends to determine if the issue has occurred before or is an isolated incident.
  4. Document Review: Evaluate documents related to the assay method to ensure compliance with established procedures.

Proper interpretation of gathered data is critical and may hinge on statistically relevant findings or laboratory norms.

Root Cause Tools

Although various root cause analysis tools can be employed, selecting the appropriate one depends on the complexity and context of the issue. The following tools are recommended:

5-Why Analysis

This straightforward technique involves repeatedly asking “why” to explore the layers of issues leading to the deviation. This method is effective for straightforward problems and helps in identifying root causes without getting lost in details.

Fishbone Diagram (Ishikawa)

This visual tool helps itemize various potential causes by categories (Materials, Methods, Machines, etc.), allowing teams to brainstorm comprehensively on visible and hidden factors contributing to assay drift.

Fault Tree Analysis

This deductive reasoning tool analyzes the pathways causing the failure, making it suitable for complex causes necessitating in-depth analysis.

Using the correct method significantly improves the chances of identifying the true root cause, thus facilitating a more targeted CAPA approach.

CAPA Strategy

Upon identifying the root cause(s), a Comprehensive Corrective and Preventative Action (CAPA) plan must be established:

  • Correction: Take immediate action to rectify any non-conformance or compliance issue. For instance, if an assay fails, it should not be released until a thorough investigation is completed.
  • Corrective Action: Develop specific actions to prevent recurrence. This might include revising SOPs, retraining personnel, or implementing new controls.
  • Preventive Action: Long-term strategies aimed at preventing similar issues in the future need to be adopted. This may require enhanced monitoring techniques, additional quality checks, or even equipment upgrades.
Pharma Tip:  Occupational exposure limit breach during inspection prep: risk assessment for patient safety

Effective CAPA helps in not only resolving the specific instance of assay drift but also minimizes the chances of future occurrences.

Control Strategy & Monitoring

Having a navigation plan is essential in maintaining assay reliability:

Statistical Process Control (SPC)

Employ SPC techniques to monitor assay performance over time, utilizing control charts to detect trends before they escalate into significant issues.

Sampling and Testing

Implement periodic testing and sampling of both materials and output to ensure ongoing compliance with established standards.

Related Reads

Alarm Systems

Utilize alarm systems for critical parameters that may impact assay performance. This ensures that deviations are detected and addressed in real-time.

Verification

Regularly verify equipment and method standards to maintain the reliability of assay results.

Building an effective control strategy enhances organizational capability and responsiveness toward any deviations that may occur.

Validation / Re-qualification / Change Control Impact

Assay drift may necessitate a review of your validation and change control processes:

  • Validation: Re-test and validate assay methods if significant deviations occur after addressing root causes.
  • Re-qualification: Equipment involved in the testing process should be re-qualified to ensure it meets acceptance criteria.
  • Change Control: If a change in procedure or equipment is identified as a root cause, ensure that proper change control procedures are followed before implementation.

This proactive approach not only addresses current issues but also fosters continuous improvement in manufacturing practices.

Inspection Readiness: What Evidence to Show

To demonstrate compliance during FDA, EMA, or MHRA inspections following an assay drift incident, ensure you have the following documentation ready:

  • Batch production and testing records reflecting traceability and adherence to protocols.
  • Investigation reports detailing all findings, actions taken, and the rationale for those actions.
  • CAPA documentation indicating corrective measures introduced and their effectiveness over time.
  • Quality assurance logs and audit reports for regular reviews performed on processes influenced by the deviation.
Pharma Tip:  Stability failure after equipment cleaning: containment CAPA and effectiveness checks

Being prepared with the right documentation fosters transparency and confidence in your organization’s commitment to quality and compliance.

FAQs

What is assay drift?

Assay drift refers to the trend of assay results deviating from established acceptance criteria over time, leading to inconsistencies in product quality.

How does assay drift affect product release?

Assay drift can result in OOS results, which can potentially lead to batch rejection and regulatory complications.

What immediate actions should be taken upon detecting assay drift?

Halt production, review batch records, isolate affected batches, notify regulatory affairs, and conduct preliminary investigations.

Which root cause analysis tool is the best for a specific situation?

The choice of tool depends on the complexity of the issue; simple problems may be resolved using 5-Why analysis, while more complex cases may benefit from Fault Tree Analysis.

What is the significance of CAPA in a deviation investigation?

CAPA is crucial for resolving non-conformances and preventing future occurrences of similar issues, thus ensuring long-term product quality.

What documentation is required for inspection readiness?

Documentation should include batch records, investigation and CAPA reports, quality assurance logs, and audit reports.

How can I monitor assay performance over time?

Implement Statistical Process Control (SPC) methodologies, along with periodic testing and monitoring of sample results.

What should be included in a change control process post-investigation?

Ensure that changes are justified, documented, assessed for impact, and communicated effectively to all relevant parties.

How can cross-contamination be controlled in shared facilities?

Implement stringent protocols for cleaning, maintenance, and segregation of operations to minimize the risk of cross-contamination.

What steps should be considered if changes to the assay method are required?

Conduct a thorough risk assessment, involve cross-functional teams, ensure validation of the new method, and update all relevant documentation.

Is it necessary to notify regulatory authorities of assay drift incidents?

Yes, regulations require that significant deviations or OOS results are reported to regulatory bodies to maintain compliance.

How often should re-qualification be conducted for testing equipment?

Re-qualification should occur regularly based on defined schedules or after significant changes in process or equipment.

What role does training play in preventing assay drift?

Continuous training ensures personnel are knowledgeable about procedures and changes, reducing human errors that may contribute to assay drift.